Here I present: “Cisplatin-Induced Hearing-Loss”, Victor McKusick, Mendelian Inheritance in Man’, 1966. (CIHL) icd10=H91.03
INTRODUCTION.
Cisplatin is a chemical compound with formula cis-[Pt(NH3)2Cl2]. It is a coordination complex of platinum that is used as a medication used to treat a number of cancers.
Cisplatin is a highly effective chemotherapeutic agent, but its use is restricted by the high incidence of irreversible ototoxicity associated with it. This ototoxicity causes serious permanent bilateral hearing loss in 10 to 25% of adults receiving the drug, and in up to 60% of children. The consequences of this ototoxicity are particularly serious in children, because even mild hearing loss can compromise language and cognitive development. Cisplatin ototoxicity frequently leads to dose reduction and premature termination of cisplatin treatment, which may affect overall survival rates.
There is evidence that cisplatin-induced hearing-loss (CIHL) is caused by mutation in the CIHL gene on cytogenetic location 6p22.3 and genomic coordinates 6:15,200,001-25,200,000. The screenshot of the CIHL gene 10,000,000 bp (base pairs) of DNA sequence length is shown BELOW. Nine (9) other genes besides CIHL in the 6p22.3 cytogenetic location are listed BENEATH.
| Coordinate | Symbol | Genomic Name |
| 6:13,924,446 | RNF182 | RING finger protein 182 |
| 6:14,117,256 | CD83 | CD83 antigen |
| 6:15,200,001 | ALPQTL3 | Alkaline phosphatase, plasma level of, QTL 3 |
| 6:15,200,001 | BWQTL4 | Birth weight quantitative trait locus 4 |
| 6:15,200,001 | CIHL | Hearing loss, cisplatin-induced |
| 6:15,200,001 | CMAHP | Cytidine monophospho-N-acetylneuraminic acid hydroxylase |
| 6:15,200,001 | DYX2 | Dyslexia, susceptibility to, 2 |
| 6:15,200,001 | NBLST4 | Neuroblastoma, susceptibility to, 4 |
| 6:15,200,001 | OTSC3 | Otosclerosis 3 |
| 6:15,246,069 | JARID2 | Jumonji and AT-rich interaction domain containing 2 |
